--- title: "GSK: Hold Rating Reaffirmed as Near-Term Strength Offsets Long-Term Uncertainties; 2,350p Price Target Maintained" type: "News" locale: "en" url: "https://longbridge.com/en/news/294183934.md" description: "Bank of America Securities reaffirmed a Hold rating on GSK with a 2,350p price target, citing near-term strength offset by long-term uncertainties. Analyst Sachin Jain noted solid Q2 EPS and maintained FY26 guidance but highlighted risks from HIV franchise loss-of-exclusivity events. Citi also maintained a Hold rating with a £21.00 target, reflecting cautious outlooks despite operational resilience." datetime: "2026-07-29T09:36:35.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294183934.md) - [en](https://longbridge.com/en/news/294183934.md) - [zh-HK](https://longbridge.com/zh-HK/news/294183934.md) generator: "portal-rs" --- # GSK: Hold Rating Reaffirmed as Near-Term Strength Offsets Long-Term Uncertainties; 2,350p Price Target Maintained In a report released yesterday, Sachin Jain from Bank of America Securities reiterated a Hold rating on GlaxoSmithKline, with a price target of p2,350.00. ### Claim 55% Off TipRanks - Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions - Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks Sachin Jain has given his Hold rating due to a combination of factors, balancing GSK’s solid near-term delivery with limited visibility on material upside. The company posted a notable second-quarter EPS beat, driven largely by one-off vaccine strength, and maintained its FY26 guidance while tilting expectations toward the upper end for both sales and EBIT, suggesting operational resilience but not a step-change in growth. At the same time, Jain highlights that GSK’s long-term story depends heavily on successful execution of key launches and the durability of its HIV franchise through upcoming loss-of-exclusivity events. While R&D is accelerating, cost savings are largely reinvested, and the >£40bn 2031 sales target is reiterated, he sees current valuation—reflected in an unchanged 2,350p price target based on modest sales CAGR assumptions—as appropriately capturing prospects, leaving insufficient conviction to argue for meaningful upside beyond existing forecasts. In another report released today, Citi also maintained a Hold rating on the stock with a £21.00 price target. ### Related Stocks - [GSK.US](https://longbridge.com/en/quote/GSK.US.md) - [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md) - [BAC.US](https://longbridge.com/en/quote/BAC.US.md) - [C.US](https://longbridge.com/en/quote/C.US.md) - [GSK.WI.US](https://longbridge.com/en/quote/GSK.WI.US.md) - [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md) - [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md) - [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md) - [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md) - [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md) - [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md) - [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md) - [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md) - [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md) - [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md) - [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md) - [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md) - [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md) - [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md) - [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md) - [8648.JP](https://longbridge.com/en/quote/8648.JP.md) - [C-R.US](https://longbridge.com/en/quote/C-R.US.md) ## Related News & Research - [GSK Races To Protect Profits Before Its HIV Blockbuster Faces Generic Rivals](https://longbridge.com/en/news/294098349.md) - [Bernstein Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)](https://longbridge.com/en/news/294085968.md) - [Man Group PLC : Form 8.3 - Senior plc](https://longbridge.com/en/news/296598007.md) - [REG - Nationwide B.S. Nationwide BS- 34VG - Results RNS - Re-sale of CCDS](https://longbridge.com/en/news/296240068.md) - [REG - Franklin Templeton Bodycote PLC - Form 8.3 - Bodycote Plc](https://longbridge.com/en/news/296242803.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**